bluebird bio is a biotechnology company pioneering advanced genetic therapies to treat severe genetic diseases and cancer.
Overview
Regulatory Milestones
History Of Bluebird Bio
Future Directions And Goals
Challenges And Controversies
Clinical Trials And Research
Therapeutic Areas And Products
Partnerships And Collaborations
Key Technologies And Innovations
Massachusetts
United States
Gene Therapy
Technology
Government
Progress
Product
Dreams
People
๐ฌ bluebird bio focuses on developing genetic therapies for severe genetic disorders.
๐ The company is known for its work in gene therapy for conditions like sickle cell disease and beta-thalassemia.
๐ข Founded in 1992, bluebird bio is headquartered in Cambridge, Massachusetts.
๐ The company went public in 2013 and has raised significant funding for its research.
๐ป bluebird bio utilizes a proprietary LentiGlobin platform for its gene therapy products.
๐งฌ bluebird bio's therapies aim to correct the genetic mutations responsible for disorders.
๐ค The company collaborates with various institutions and organizations to enhance research.
๐ bluebird bio is committed to addressing global health challenges through innovative therapies.
๐ In 2021, bluebird bio received FDA approval for its first gene therapy product, Zynteglo.
๐ก The company's mission is to provide transformative therapies that change patients' lives.